<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3. Discussion</segment>
<segment id="2" parent="1003" relname="span">Kounis syndrome is defined as acute coronary syndromes</segment>
<segment id="3" parent="2" relname="restatement">( ACS )</segment>
<segment id="4" parent="1003" relname="elaboration">induced by hypersensitivity and anaphylactic reaction .</segment>
<segment id="5" parent="1006" relname="span">Several causes are reported</segment>
<segment id="6" parent="5" relname="purpose">to induce Kounis syndrome , such as medicines , environmental exposures , bee stings , and asthma</segment>
<segment id="7" parent="1006" relname="elaboration">( Table 2 ) .</segment>
<segment id="8" parent="1004" relname="joint">Ayhan Akoz et al. conducted a prospective study</segment>
<segment id="9" parent="1004" relname="joint">and found the incidence of Kounis syndrome in all admissions to be 19.4/100,000 .</segment>
<segment id="10" parent="1010" relname="span">The most common etiology</segment>
<segment id="11" parent="1011" relname="span">reported was the use of medications ,</segment>
<segment id="12" parent="11" relname="elaboration">accounting for about 81 % .</segment>
<segment id="13" parent="1004" relname="joint">In the current concept , three variants of Kounis syndrome have been described .</segment>
<segment id="14" parent="1014" relname="span">Type I variant is characterized by allergy-related coronary spasm without coronary lesions or risk factors .</segment>
<segment id="15" parent="1015" relname="joint">Patients with type I Kounis syndrome present electrocardiographic change with or without cardiac enzymes elevation</segment>
<segment id="16" parent="1016" relname="span">due to the acute release of inflammatory mediators</segment>
<segment id="17" parent="16" relname="elaboration">inducing coronary spasm .</segment>
<segment id="18" parent="1004" relname="joint">The type II variant includes pre-existing atheromatous disease .</segment>
<segment id="19" parent="1019" relname="span">An acute allergic reaction</segment>
<segment id="20" parent="1020" relname="span">leading to the release of inflammatory mediators induces plaque erosion or rupture ,</segment>
<segment id="21" parent="20" relname="elaboration">which causes acute myocardial infarction .</segment>
<segment id="22" parent="1021" relname="joint">Type III has been defined in patients with pre-existing coronary disease and coronary artery stent thrombosis .</segment>
<segment id="23" parent="1024" relname="span">In the Jack P. Chen et al. study , the pathology of drug-eluting stent</segment>
<segment id="24" parent="23" relname="restatement">( DES )</segment>
<segment id="25" parent="1023" relname="same_unit">thrombosis in these patients presented with eosinophils and mast cell infiltration in Giemsa and hematoxylin – eosin staining .</segment>
<segment id="26" parent="1025" relname="joint">In the Stéphane Cook et al. study , the association with late DES thrombosis and local inflammation in histopathology was reported .</segment>
<segment id="27" parent="1025" relname="joint">In intravascular ultrasound analysis , vessel remodeling was also confirmed .</segment>
<segment id="28" parent="1028" relname="preparation">Very late stent thrombosis is recognized as a feature of Kounis syndrome (</segment>
<segment id="29" parent="1029" relname="preparation">Figure 5</segment>
<segment id="30" parent="1030" relname="preparation">) .</segment>
<segment id="31" parent="1031" relname="preparation">The detail pathophysiological mechanisms remain elusive .</segment>
<segment id="32" parent="1032" relname="preparation">In the current concept , Kounis syndrome is related to inflammatory cell and mast cell-associated disorders .</segment>
<segment id="33" parent="1033" relname="span">Local inflammatory cell interactions induce hypersensitivity and anaphylactic results</segment>
<segment id="34" parent="33" relname="means">by releasing inflammatory mediators after activation .</segment>
<segment id="35" parent="1035" relname="span">In the Nicholas G. Kounis et al. summary , Kounis syndrome is a complex multisystem disease</segment>
<segment id="36" parent="35" relname="elaboration">accompanied by allergy – hypersensitivity – anaphylaxis .</segment>
<segment id="37" parent="1037" relname="span">During hypersensitivity , the mast cells and lymphocytes release inflammatory mediators ,</segment>
<segment id="38" parent="1038" relname="span">promoting an allergic reaction</segment>
<segment id="39" parent="38" relname="elaboration">via a high serum level of histamine , proteases , arachidonic acid products , and chemokines .</segment>
<segment id="40" parent="1034" relname="joint">These factors cause platelet aggregating and tissue factor expression .</segment>
<segment id="41" parent="1041" relname="span">The proteases also induce plaque erosion and rupture</segment>
<segment id="42" parent="1042" relname="span">by activating matrix metalloproteinase</segment>
<segment id="43" parent="42" relname="restatement">( MMP ) .</segment>
<segment id="44" parent="1034" relname="joint">The downstream mediators induce vasoconstriction</segment>
<segment id="45" parent="1034" relname="joint">and worsen coronary vasospasm .</segment>
<segment id="46" parent="1046" relname="span">The diagnosis of Kounis syndrome is based on clinical symptoms and cardiac surveys ,</segment>
<segment id="47" parent="46" relname="elaboration">including cardiac enzyme , electrocardiographic , echocardiographic , and angiography .</segment>
<segment id="48" parent="1048" relname="preparation">The serum level of tryptase and histamine can provide more information about the allergic reaction (</segment>
<segment id="49" parent="50" relname="preparation">Figure 5</segment>
<segment id="50" parent="1049" relname="span">) .</segment>
<segment id="51" parent="1051" relname="span">Tajda Keber et al. suggested measuring cardiac enzymes in acute allergic reaction patients as necessary</segment>
<segment id="52" parent="1052" relname="joint">to diagnose Kounis syndrome promptly</segment>
<segment id="53" parent="1052" relname="joint">and manage cardiac injury early and appropriately .</segment>
<segment id="54" parent="1055" relname="span">Echocardiography and coronary angiography can provide detailed information</segment>
<segment id="55" parent="54" relname="purpose">to rule out takotsubo cardiomyopathy or other cardiac disorders in cardiac wall motion abnormalities patients .</segment>
<segment id="56" parent="1058" relname="attribution">Keita Goto et al. reported</segment>
<segment id="57" parent="1058" relname="span">that thallium-201</segment>
<segment id="58" parent="57" relname="restatement">( Tl )</segment>
<segment id="59" parent="1060" relname="span">single-photon emission CT</segment>
<segment id="60" parent="59" relname="restatement">( SPECT )</segment>
<segment id="61" parent="1062" relname="span">and 125I-15-(p-iodophenyl)-3-(R , S)-methylpentadecanoic acid</segment>
<segment id="62" parent="61" relname="restatement">( BMIPP )</segment>
<segment id="63" parent="1063" relname="span">SPECT</segment>
<segment id="64" parent="1064" relname="joint">were conducted in a post-Kounis syndrome patient ,</segment>
<segment id="65" parent="1064" relname="joint">and they revealed a local perfusion defect with decreased BMIPP uptake .</segment>
<segment id="66" parent="1048" relname="joint">Aylin Okur et al. included 26 patients with known or suspected Kounis syndrome</segment>
<segment id="67" parent="1048" relname="joint">and conducted contrast-enhanced magnetic resonance imaging .</segment>
<segment id="68" parent="1067" relname="span">The results revealed an early-phase subendocardial contrast defect and local edema in lesion areas in T2-weighted images .</segment>
<segment id="69" parent="1069" relname="span">These newer images provide a reliable study</segment>
<segment id="70" parent="69" relname="purpose">to assess cardiac injury in Kounis syndrome .</segment>
<segment id="71" parent="1070" relname="joint">Compared to the majority of ACS subjects , the therapeutic strategy of Kounis syndrome should focus on both the cardiac injury and allergic reaction .</segment>
<segment id="72" parent="1071" relname="joint">Sometimes , the two different conditions may require opposing treatments .</segment>
<segment id="73" parent="1073" relname="span">In the current concept , the administration of medicine should avoid promoting an allergy reaction</segment>
<segment id="74" parent="73" relname="elaboration">and aggravating the cardiac injury .</segment>
<segment id="75" parent="1076" relname="span">Intravenous corticosteroids</segment>
<segment id="76" parent="77" relname="preparation">( hydrocortisone :</segment>
<segment id="77" parent="1077" relname="span">1 – 2 mg/kg/day )</segment>
<segment id="78" parent="1080" relname="span">and antihistamine agents</segment>
<segment id="79" parent="78" relname="elaboration">( diphenhydramine : 1 – 2 mg/kg )</segment>
<segment id="80" parent="1079" relname="same_unit">are useful</segment>
<segment id="81" parent="1079" relname="purpose">to control the allergic reaction .</segment>
<segment id="82" parent="1082" relname="span">Aspirin is , however , potentially detrimental</segment>
<segment id="83" parent="1083" relname="span">because of cyclooxygenase inhibition ,</segment>
<segment id="84" parent="83" relname="result">promoting arachidonic acid release into the leukotriene pathway .</segment>
<segment id="85" parent="1085" relname="span">Calcium channel blockers and nitrates can relieve the vasospasm .</segment>
<segment id="86" parent="85" relname="elaboration">In hemodynamically unstable patients , nitrates may not be appropriate due to their hypotension properties .</segment>
<segment id="87" parent="1087" relname="span">Opioids may induce mast cell degeneration ,</segment>
<segment id="88" parent="87" relname="elaboration">which may worsen the anaphylaxis .</segment>
<segment id="89" parent="1089" relname="span">Beta-blockers should be used with extreme caution</segment>
<segment id="90" parent="1090" relname="joint">because they can exaggerate coronary spasms</segment>
<segment id="91" parent="1090" relname="joint">and cause epinephrine to be ineffective .</segment>
<segment id="92" parent="1091" relname="joint">Epinephrine is the only life-saving drug in the event of aggravated ischemia , vasospasm , and arrhythmias .</segment>
<segment id="93" parent="1093" relname="span">In some animal studies , adrenaline may cause LV impairment and not recovery in established anaphylactic shock .</segment>
<segment id="94" parent="93" relname="elaboration">Therefore , adrenaline is only suggested in high-grade anaphylactic reactions .</segment>
<segment id="95" parent="1094" relname="joint">Adequate fluids</segment>
<segment id="96" parent="1095" relname="joint">resuscitation and oxygen therapy are important supportive treatments for Kounis syndrome .</segment>
<segment id="97" parent="1096" relname="span">Type II variant patients can take advantage of an ACS protocol .</segment>
<segment id="98" parent="1098" relname="span">Double antiplatelet therapy in the pharmacological treatment of myocardial revascularization is suggested ,</segment>
<segment id="99" parent="1100" relname="span">including acetylsalicylic acid</segment>
<segment id="100" parent="99" relname="restatement">( ASA )</segment>
<segment id="101" parent="1099" relname="same_unit">and another P2Y12 receptor inhibitor .</segment>
<segment id="102" parent="1102" relname="span">In the type III variant , the ACS protocol</segment>
<segment id="103" parent="102" relname="elaboration">accompanied by urgent aspiration of intrastent thrombus is suggested (</segment>
<segment id="104" parent="1103" relname="joint">Figure 5</segment>
<segment id="105" parent="1104" relname="joint">) .</segment>
<segment id="106" parent="1104" relname="joint">Antihistamines , corticosteroids , and mast cell stabilizers may be helpful for allergic symptoms after stent implantation or revascularization .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1004" relname="background"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1005" type="span" parent="1004" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1010" type="span" parent="1004" relname="joint"/>
<group id="1011" type="span" parent="10" relname="elaboration"/>
<group id="1014" type="span" parent="1004" relname="joint"/>
<group id="1015" type="multinuc" parent="14" relname="elaboration"/>
<group id="1016" type="span" parent="1015" relname="joint"/>
<group id="1018" type="span" parent="1004" relname="joint"/>
<group id="1019" type="span" parent="1021" relname="preparation"/>
<group id="1020" type="span" parent="19" relname="elaboration"/>
<group id="1021" type="multinuc" parent="1018" relname="span"/>
<group id="1022" type="multinuc" parent="1021" relname="joint"/>
<group id="1023" type="multinuc" parent="1022" relname="sequence"/>
<group id="1024" type="span" parent="1023" relname="same_unit"/>
<group id="1025" type="multinuc" parent="1022" relname="sequence"/>
<group id="1027" type="span" parent="1025" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="span"/>
<group id="1029" type="span" parent="1028" relname="span"/>
<group id="1030" type="span" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="span"/>
<group id="1032" type="span" parent="1031" relname="span"/>
<group id="1033" type="span" parent="1034" relname="preparation"/>
<group id="1034" type="multinuc" parent="1032" relname="span"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1037" type="span" parent="1034" relname="joint"/>
<group id="1038" type="span" parent="37" relname="result"/>
<group id="1041" type="span" parent="1034" relname="joint"/>
<group id="1042" type="span" parent="41" relname="means"/>
<group id="1046" type="span" parent="1034" relname="joint"/>
<group id="1047" type="span" parent="1034" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="span"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1051" type="span" parent="1048" relname="joint"/>
<group id="1052" type="multinuc" parent="51" relname="purpose"/>
<group id="1054" type="span" parent="1048" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="span"/>
<group id="1056" type="span" parent="1055" relname="elaboration"/>
<group id="1057" type="span" parent="1056" relname="span"/>
<group id="1058" type="span" parent="1057" relname="span"/>
<group id="1059" type="multinuc" parent="1057" relname="elaboration"/>
<group id="1060" type="span" parent="1059" relname="joint"/>
<group id="1061" type="multinuc" parent="1059" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="same_unit"/>
<group id="1063" type="span" parent="1061" relname="same_unit"/>
<group id="1064" type="multinuc" parent="63" relname="elaboration"/>
<group id="1067" type="span" parent="1048" relname="joint"/>
<group id="1068" type="multinuc" parent="68" relname="elaboration"/>
<group id="1069" type="span" parent="1068" relname="joint"/>
<group id="1070" type="multinuc" parent="1068" relname="joint"/>
<group id="1071" type="multinuc" parent="1070" relname="joint"/>
<group id="1072" type="multinuc" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="joint"/>
<group id="1074" type="multinuc" parent="1072" relname="joint"/>
<group id="1075" type="multinuc" parent="1074" relname="joint"/>
<group id="1076" type="span" parent="1075" relname="same_unit"/>
<group id="1077" type="span" parent="75" relname="elaboration"/>
<group id="1078" type="span" parent="1075" relname="same_unit"/>
<group id="1079" type="multinuc" parent="1078" relname="span"/>
<group id="1080" type="span" parent="1079" relname="same_unit"/>
<group id="1081" type="multinuc" parent="1074" relname="joint"/>
<group id="1082" type="span" parent="1081" relname="joint"/>
<group id="1083" type="span" parent="82" relname="cause"/>
<group id="1084" type="multinuc" parent="1081" relname="joint"/>
<group id="1085" type="span" parent="1084" relname="joint"/>
<group id="1086" type="multinuc" parent="1084" relname="joint"/>
<group id="1087" type="span" parent="1086" relname="joint"/>
<group id="1088" type="span" parent="1086" relname="joint"/>
<group id="1089" type="span" parent="1088" relname="span"/>
<group id="1090" type="multinuc" parent="89" relname="cause"/>
<group id="1091" type="multinuc" parent="1089" relname="elaboration"/>
<group id="1092" type="multinuc" parent="1091" relname="joint"/>
<group id="1093" type="span" parent="1092" relname="joint"/>
<group id="1094" type="multinuc" parent="1092" relname="joint"/>
<group id="1095" type="multinuc" parent="1094" relname="joint"/>
<group id="1096" type="span" parent="1095" relname="joint"/>
<group id="1097" type="multinuc" parent="97" relname="elaboration"/>
<group id="1098" type="span" parent="1097" relname="joint"/>
<group id="1099" type="multinuc" parent="98" relname="elaboration"/>
<group id="1100" type="span" parent="1099" relname="same_unit"/>
<group id="1101" type="span" parent="1097" relname="joint"/>
<group id="1102" type="span" parent="1101" relname="span"/>
<group id="1103" type="multinuc" parent="1102" relname="evidence"/>
<group id="1104" type="multinuc" parent="1103" relname="joint"/>
	</body>
</rst>
